Skip to main content

Advertisement

SpringerLink
Log in

Alzheimer’s amyloid-β drug hangs in the balance

  • News Feature
  • Published:

From Nature Aging

View current issue Submit your manuscript

The latest spat over the potential approval of aducanumab, an amyloid-β-targeting drug for Alzheimer’s disease, highlights continuing controversy over the amyloid-β hypothesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Massie, T. Statistical review aducanumab in Alzheimer’s. FDA https://collaboration.fda.gov/pradgevcxis7 (2020).

  2. Mintun, M. A. et al. New Engl. J. Med. https://doi.org/10.1056/NEJMoa2100708 (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Freelance journalist, Haddon Township, NJ, USA

    Mark Zipkin

Authors
  1. Mark Zipkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Zipkin.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zipkin, M. Alzheimer’s amyloid-β drug hangs in the balance. Nat Aging 1, 324–326 (2021). https://doi.org/10.1038/s43587-021-00059-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43587-021-00059-x

  • Springer Nature America, Inc.

Search

Navigation